T

Tikun Olam Cannbit Pharmaceuticals Ltd
TASE:TKUN

Watchlist Manager
Tikun Olam Cannbit Pharmaceuticals Ltd
TASE:TKUN
Watchlist
Price: 37.6 ILS 4.44% Market Closed
Market Cap: 32.7m ILS
Section:
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one TKUN stock under the Base Case scenario is 56.02 ILS. Compared to the current market price of 37.6 ILS, Tikun Olam Cannbit Pharmaceuticals Ltd is Undervalued by 33%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TKUN Relative Value
Base Case
56.02 ILS
Undervaluation 33%
Relative Value
Price
T
Worst Case
Base Case
Best Case

Valuation Multiples

0.9
P/S
P/S
Price to Sales
0.9
vs History
58
vs Industry
76
Median 3Y
0.8
Median 5Y
1.1
Industry
2.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-1.1
Industry
22.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
43
Median 3Y
-8.1
Median 5Y
-9.6
Industry
16.8
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5.2
Median 5Y
-9.3
Industry
23
More Details
13.2
P/B
P/B
Price to Book Value
13.2
vs History
4
vs Industry
34
Median 3Y
1
Median 5Y
2.2
Industry
2.3
More Details
1.4
EV/S
EV/S
Enterprise Value to Sales
1.4
vs History
58
vs Industry
71
Median 3Y
1.2
Median 5Y
1.4
Industry
2.8
More Details
Negative
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
30
Median 3Y
-13.6
Median 5Y
-16.1
Industry
5.5
More Details
2.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
2.6
vs History
7
vs Industry
50
Median 3Y
1.4
Median 5Y
-3.9
Industry
13
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-4.5
Industry
16.4
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
38
Median 3Y
-11.9
Median 5Y
-12.7
Industry
15.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
32
Median 3Y
-8
Median 5Y
-9.6
Industry
17.4
More Details
2.1
EV/IC
EV/IC
Enterprise Value to IC
2.1
vs History
30
vs Industry
49
Median 3Y
0.9
Median 5Y
1.4
Industry
2
More Details

Multiples Across Competitors

TKUN Competitors Multiples
Tikun Olam Cannbit Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IL
Tikun Olam Cannbit Pharmaceuticals Ltd
TASE:TKUN
32.7m ILS 0.9 -0.8 2.6 -4.3
US
Eli Lilly and Co
NYSE:LLY
781.6B USD 14.7 56.6 33.4 36.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
458.3B USD 5 18.2 15.1 19.6
CH
Roche Holding AG
SIX:ROG
215.9B CHF 3.5 22.9 10.5 11.8
UK
AstraZeneca PLC
LSE:AZN
194.3B GBP 4.6 31.2 114 170.5
CH
Novartis AG
SIX:NOVN
201.5B CHF 4.6 18.6 11.1 14.8
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.9 13.7 10 11.1
US
Merck & Co Inc
NYSE:MRK
220.1B USD 3.5 13.4 8.6 10.2
IE
Endo International PLC
LSE:0Y5F
195.2B USD 84.2 -66.8 310 777.4
US
Pfizer Inc
NYSE:PFE
140.8B USD 2.2 13.1 7.4 10.2
P/E Multiple
Earnings Growth PEG
IL
T
Tikun Olam Cannbit Pharmaceuticals Ltd
TASE:TKUN
Average P/E: 23.5
Negative Multiple: -0.8 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
56.6
49%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
18.2
29%
0.6
CH
Roche Holding AG
SIX:ROG
22.9
29%
0.8
UK
AstraZeneca PLC
LSE:AZN
31.2
37%
0.8
CH
Novartis AG
SIX:NOVN
18.6
18%
1
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
9%
1.5
US
Merck & Co Inc
NYSE:MRK
13.4
16%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -66.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
13.1
31%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IL
T
Tikun Olam Cannbit Pharmaceuticals Ltd
TASE:TKUN
Average EV/EBITDA: 397.2
2.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.4
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.1
8%
1.9
CH
Roche Holding AG
SIX:ROG
10.5
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
114
10%
11.4
CH
Novartis AG
SIX:NOVN
11.1
6%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
10
6%
1.7
US
Merck & Co Inc
NYSE:MRK
8.6
7%
1.2
IE
E
Endo International PLC
LSE:0Y5F
310
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IL
T
Tikun Olam Cannbit Pharmaceuticals Ltd
TASE:TKUN
Average EV/EBIT: 1 876.4
Negative Multiple: -4.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.2
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
19.6
14%
1.4
CH
Roche Holding AG
SIX:ROG
11.8
6%
2
UK
AstraZeneca PLC
LSE:AZN
170.5
22%
7.7
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
6%
1.9
US
Merck & Co Inc
NYSE:MRK
10.2
9%
1.1
IE
E
Endo International PLC
LSE:0Y5F
777.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1

See Also

Summary
TKUN intrinsic value, competitors valuation, and company profile.
DCF Valuation
TKUN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TKUN stock valuation using valuation multiples.
Wall Street Estimates
TKUN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TKUN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 292,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.